Go Ad-Free
logoThe People's Perspective on Medicine

New Biomarker Technology to Diagnose Infections Quickly and Accurately

New biomarker technology uses the immune system's response to pathogens to identify the cause of an infection.

Diagnosing infectious diseases accurately and in a timely fashion remains challenging. Mistaking a sore throat caused by Fusobacterium for one caused by more common Streptococcus can be deadly. Even distinguishing between COVID-19 and the flu can sometimes be challenging. Culturing bacteria or viruses from patient samples remains the gold standard, but it is also time consuming, difficult and not always accurate. New biomarker technology may help solve this problem in the future.

New Biomarker Technology to Aid Diagnosis:

Scientists at Icahn School of Medicine at Mount Sinai and Yale School of Medicine have identified biomarkers that may identify infections more rapidly and accurately (Cell Systems, Dec. 21, 2022). Rapid diagnosis is crucial to help doctors avoid treating viral infections with antibiotics, for example.

Current diagnostic technology such as culture or PCR assays or antigen-binding assays may fail to signal an infection early in its course. The scientists have found, however, that the immune system responds rapidly when it encounters pathogens. Some of these are part of a general response to infection. An activated group of genes leaves a distinctive fingerprint that can be detected with the new biomarker technology.

The researchers have applied the new biomarker technology to COVID-19. They are striving to develop signals that detect infection quickly and consistently, but do not cross-react with other pathogens. According to the investigators, cross-reactivity is common.

They note, though:

“Despite this, it is possible to generate viral signatures that are not cross-reactive with any bacterial class.”

The authors acknowledge that their work is preliminary, but the principles should apply to many other infectious diseases. Other scientists will need to contribute studies of infections to develop this new biomarker technology into a tool that doctors can use in clinical settings.

Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
4.5- 45 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies..
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Citations
  • Chawla DG et al, "Benchmarking transcriptional host response signatures for infection diagnosis." Cell Systems, Dec. 21, 2022. DOI:https://doi.org/10.1016/j.cels.2022.11.007
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.